TTY Biopharm Company Limited (TPEX:4105)

TTY Biopharm Company Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	2,713	2,773	2,621	2,357	2,222	2,224
Short-Term Investments	88.88	309.02	195.54	326.86	372.65	342.4
Cash & Short-Term Investments	2,802	3,082	2,817	2,684	2,595	2,566
Cash Growth	-2.80%	9.41%	4.93%	3.44%	1.12%	-11.66%
Accounts Receivable	1,716	1,354	1,344	1,227	1,138	1,033
Other Receivables	20.3	23.18	28.81	29.68	13.62	16.48
Receivables	1,736	1,377	1,373	1,257	1,151	1,050
Inventory	1,417	1,270	1,096	1,039	955.01	1,111
Prepaid Expenses	74.91	57.91	79.02	49.89	46.96	64.15
Other Current Assets	261.06	6.67	6.36	5.37	1.15	8.01
Total Current Assets	6,291	5,793	5,370	5,035	4,749	4,799
Property, Plant & Equipment	2,221	2,246	2,287	2,433	2,519	2,585
Long-Term Investments	2,128	1,945	1,578	1,496	1,432	1,458
Goodwill	247.9	247.9	-	-	-	-
Other Intangible Assets	163.05	123.44	164.01	250.75	124.9	132.9
Long-Term Deferred Tax Assets	58.51	58.52	48.71	47.1	63.72	61.8
Other Long-Term Assets	436.08	448.25	426.94	337.89	407.19	324.72
Total Assets	11,545	10,863	9,875	9,601	9,296	9,361
Accounts Payable	312.73	326.16	294.66	289.4	187.27	159.44
Short-Term Debt	1,500	1,200	1,450	1,370	1,711	1,715
Current Portion of Long-Term Debt	400	400	-	418.85	407.91	16.54
Current Portion of Leases	6.85	0.93	5.86	3.92	7.62	-
Current Income Taxes Payable	211.61	228.8	156.97	149.52	150.39	110.13
Current Unearned Revenue	33.77	34.34	14.23	33.13	39.77	16.29
Other Current Liabilities	663.72	672.18	662.02	652.62	547.55	531.2
Total Current Liabilities	3,129	2,862	2,584	2,917	3,052	2,549
Long-Term Debt	100	100	400	9.6	4.15	412.05
Long-Term Leases	7.37	10.2	3.05	3.04	14.16	-
Pension & Post-Retirement Benefits	17.21	17.54	27.4	40.81	52.6	45.5
Long-Term Deferred Tax Liabilities	359.24	359.24	318.75	305.44	260.52	271.83
Other Long-Term Liabilities	269.28	2.44	35.83	91.03	146.23	4.7
Total Liabilities	3,882	3,352	3,369	3,367	3,529	3,283
Common Stock	2,487	2,487	2,487	2,487	2,487	2,487
Additional Paid-In Capital	317.56	317.04	316.62	312.18	311.88	338
Retained Earnings	4,100	3,888	3,182	2,925	2,568	2,759
Comprehensive Income & Other	-42.1	58.69	-43.79	-64.78	-198.07	-133.71
Total Common Equity	6,862	6,750	5,941	5,658	5,168	5,450
Minority Interest	801.33	760.49	564.8	574.86	599.38	628.3
Shareholders' Equity	7,663	7,511	6,506	6,233	5,767	6,078
Total Liabilities & Equity	11,545	10,863	9,875	9,601	9,296	9,361
Total Debt	2,014	1,711	1,859	1,805	2,145	2,144
Net Cash (Debt)	787.91	1,371	957.65	878.78	450	422.47
Net Cash Growth	38.08%	43.11%	8.97%	95.28%	6.52%	-56.51%
Net Cash Per Share	3.16	5.50	3.84	3.53	1.81	1.70
Filing Date Shares Outstanding	248.65	248.65	248.65	248.65	248.65	248.65
Total Common Shares Outstanding	248.65	248.65	248.65	248.65	248.65	248.65
Working Capital	3,162	2,931	2,787	2,118	1,698	2,250
Book Value Per Share	27.60	27.15	23.89	22.76	20.78	21.92
Tangible Book Value	6,451	6,379	5,777	5,408	5,043	5,317
Tangible Book Value Per Share	25.94	25.65	23.23	21.75	20.28	21.38
Land	902.9	902.9	902.9	902.9	902.9	902.9
Buildings	1,492	1,479	1,461	1,432	1,420	1,311
Machinery	1,437	1,446	1,432	1,418	1,359	1,234
Construction In Progress	75.42	0.59	8.95	77.09	95	323.33

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.